CClinicalTrials.gg
CompletedNCT00653718AIMSUpdated Aug 24, 2020

Musculoskeletal Pain in Postmenopausal, Early Breast Cancer Patients Receiving Aromatase Inhibitor Therapy - A Pilot Study

An observational study in Breast Cancer, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Completed at 1 site in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-08-24.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Observational

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
Female
01

Study summary

In 2005, the EBCIG demonstrated the efficacy of tamoxifen in improving overall survival in hormone receptor positive breast cancers. However, tamoxifen shows partial estrogen agonist activity, which is responsible for the drug's detrimental effects such as endometrial carcinoma, thromboembolism, and tamoxifen resistance. More recently, aromatase inhibitors have been shown to be superior to tamoxifen in the metastatic and adjuvant settings. The ATAC trial demonstrated improved disease-free survival (DFS) for 5 years of anastrozole compared to 5 years of tamoxifen 3. The BIG 1-98 trial results demonstrated that after a median follow-up of 25.8 months, letrozole improved DFS and distant DFS when compared to tamoxifen. Based on these results, adjuvant hormonal therapy with Aromatase Inhibitors (AI) has become the preferred therapy for post-menopausal woman.

However, AI therapy is also associated with toxicities that merit in-depth studies, one of them being an increase in musculoskeletal pain. In the ATAC trial, at a median follow-up of 5.7 years, arthralgia was significantly higher (35.6% vs. 29.4%) and fractures were also increased (11.0% vs. 7.7%) when anastrozole was administered for 5 years following surgery with or without chemotherapy 3. The incidence of arthralgia was also significantly higher in the MA-17 trial, with 25% of patients receiving letrozole developing arthralgia compared with 21% in the placebo group following 5 to 6 years of tamoxifen 5.

Traditionally in cancer clinical trials, the reporting of musculoskeletal pain has been based on the "Common Terminology Criteria for Adverse Events", which covers a wide range of symptoms and does not facilitate the documentation of a pain syndrome in a specific manner. Therefore, there is a need to design a study that will describe the nature of the pain associated with the administration of AI therapy using tools that have been validated for capturing a multidimensional phenomenon such as pain.

02

Conditions studied

  • Breast Cancer

Keywords

  • Pain
  • Characterize musculoskeletal pain
  • Breast cancer patients treated with aromatase inhibitors
03

In context

Breast Neoplasms

12,544 studies on the registry are indexed under Breast Neoplasms; 2,892 are open to participants now.

This study's enrollment of 30 is below the median of 184 across 2,642 observational studies indexed under Breast Neoplasms.

Browse Breast Neoplasms studies →

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 370 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Early breast cancer patients

Inclusion criteria

  • Female
  • Invasive carcinoma of the breast confirmed by needle biopsy or final pathological evaluation of the surgical specimen
  • Breast cancer Stage I, II or IIIa
  • ER and/or PR+
  • No evidence of metastatic disease
  • Post-menopausal
  • May or may not have received adjuvant or neoadjuvant chemotherapy
  • Bilateral infiltrating carcinoma are eligible

Exclusion criteria

Exclusion Criteria:

  • Men not eligible
  • Other malignancies
  • Patients who have received neoadjuvant or adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor
  • Ongoing treatment with any sex hormonal therapy (these patients are eligible if this therapy is discontinued prior to entry)
  • Therapy with hormonal agent such as raloxifene for osteoporosis
  • Patients receiving glucocorticoids
  • Psychiatric or addictive disorders
  • Inability to read English or French
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
30 participants (actual)
06

What researchers measure

Primary outcomes

  1. Musculoskeletal pain

    Time frame: Every two weeks

Secondary outcomes

  1. Lymphocyte gene expression profiling

    Time frame: Every two weeks

07

Study locations

1 site
  • Centre hospitalier de l'Université de Montréal
    Montréal, Quebec H2W 1T8, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00653718
Lead sponsor
Centre hospitalier de l'Université de Montréal (CHUM)
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Apr 7, 2008
Start date
May 2008
Primary completion
Jul 2008
Completion
Dec 2008
Last update
Aug 24, 2020

Study contacts

André Robidoux, MD
principal investigator · Centre hospitalier de l'Université de Montréal (CHUM)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2008. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion